Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
about
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePosaconazole: an oral triazole with an extended spectrum of activityHyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats.Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodSteady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionPosaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infectionEffect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Human pharmacogenomic variations and their implications for antifungal efficacy.Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.Posaconazole: clinical pharmacology and potential for management of fungal infections.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug SolubilizationPharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy menNewer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleRole of posaconazole in the management of oropharyngeal and esophageal candidiasisPosaconazole: a new broad-spectrum antifungal agent.
P2860
Q26771180-C00BE458-29D9-415A-8C25-E27F78A8DE12Q27009221-AD753F49-0A65-4DF3-8476-CCD727E09904Q28291282-CE330CAA-0233-4457-B7D4-56EC317BC802Q33665165-9A05D9D6-8137-4531-B0D0-786EC4B52533Q33694804-1F6FABC3-21B0-4414-9C45-C0EB50FF024FQ33764269-7EF3227A-0DC5-487F-BD66-5B5E83DCD1C9Q33798286-C00986A2-23CC-4C58-9AD8-A24E3D220513Q33798313-BDF1321A-6BD8-4E16-8068-01228833486EQ34108484-0672AA8E-AE67-4F73-891E-BD4E74559E03Q34108650-A9DDFDB1-E06C-4E61-8224-62F52540392EQ34299092-6AFD66AE-F99E-4BCC-8C45-8CD7E43599B3Q34309527-EA7D193A-382D-4EF3-B82E-01D038FE1BF6Q34352014-8C190239-5023-48DE-92E8-2D4879022008Q34498982-43B64F66-C5AE-4225-B0C2-616FE5A8AB51Q34505582-339FDBB8-4F8D-4427-B3A7-54DCFC1BA223Q34633796-F07BA138-36A9-4A88-BAC4-9917559C89E8Q34648517-4CA3D2C0-EEBA-4C71-AC25-AFE3A2733079Q34680655-6BF6CA5E-7CA2-43B9-A5F6-BB2A24993669Q35026481-FCC6F9A4-C9E8-48B8-B8C9-B9888286F7FBQ35070838-37E30141-548C-4697-B753-8556C054E32DQ35105840-93EA3C33-CE12-4968-95E4-A2E0CE524838Q35607672-0ACD326F-BF47-4B38-8A8C-263B8F535E3CQ35635971-99023CC3-92A3-49CC-8E08-1EAC2A8B2232Q35647678-27AC5BFF-65A7-4EEB-9290-2E758DCB5C37Q35859959-474D550B-4F58-4B45-B4F0-9F9837B3F136Q35941414-7BC0E603-503D-47C0-ACBE-F1905D8C4ADBQ35959476-F8B29DA1-6B7B-4525-96CD-0C089F428A67Q35960882-1C1B9B18-5D10-406C-85FE-AC85293CAA74Q36018743-0DAC726C-018B-4BB3-A7C9-E7752DF0F672Q36171677-A2340A87-C23F-4ADB-BBF0-3B71B933E2A9Q36233491-B9562B67-AD95-468B-8358-2F059FBA4AF3Q36276966-81181506-1B9F-4780-BF97-DA5DAE879DE9Q36308059-343FC48D-A51D-48D9-A0D2-22E380D2B61CQ36396203-D0A9A8AB-2403-488F-ABA9-CC6BD0602ADAQ36446679-7288A27C-B7AA-4ECD-9CFE-C381DDF0FE85Q36489989-ED49C1AD-75D6-4E07-B187-089BEEC9463AQ36491819-40920370-9E55-4EE9-A39F-07E70F216D0BQ36521993-14CA2216-7A4A-4D67-9B42-A8315A6804C4Q36642964-EDB9CF92-908E-437B-B957-36B7D8E6F5E2Q36828159-F237B5A4-0924-4279-8983-7933B3749C3F
P2860
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Effect of food on the relative ...... osaconazole in healthy adults.
@ast
Effect of food on the relative ...... osaconazole in healthy adults.
@en
type
label
Effect of food on the relative ...... osaconazole in healthy adults.
@ast
Effect of food on the relative ...... osaconazole in healthy adults.
@en
prefLabel
Effect of food on the relative ...... osaconazole in healthy adults.
@ast
Effect of food on the relative ...... osaconazole in healthy adults.
@en
P2093
P2860
P1476
Effect of food on the relative ...... osaconazole in healthy adults.
@en
P2093
David Wexler
Elaine Radwanski
Josephine Lim
Mark Laughlin
Rachel Courtney
P2860
P304
P356
10.1046/J.1365-2125.2003.01977.X
P407
P577
2004-02-01T00:00:00Z